ERBB2 and breast cancer: High levels of ct-miR-21, ct-miR-4734, and ct-miR-150-5p have been associated with poor clinical outcome in HER2-positive non metastatic BC patients treated with NAT, or adjuvant therapy ± trastuzumab [12,13].